Clinical Trial

Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus

Name: Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus — clinical trial record (NCT06085378)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TK-SEEK

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.

Trial Details

NCT Number	NCT06085378
Lead Sponsor	First Affiliated Hospital, Sun Yat-Sen University
Conditions	Acute Ischemic Stroke, Type 2 Diabetes
Enrollment	630 participants
Start Date	2024-01-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2023-10-16